OPEN END-TURBO-OPTIONSSCHEIN - AMGEN | Real-time BOERSE MUENCHEN 10:37:20 27/06/2024 BST | ||
| 10.13 EUR | 0.00% |
|
| Current month | +9.75% | ||
| 1 month | +6.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 10.13 | 0.00% |
| 26/06/24 | 10.13 | -5.15% |
| 25/06/24 | 10.68 | +2.99% |
| 24/06/24 | 10.37 | +5.49% |
| 21/06/24 | 9.83 | +0.92% |
Real-time BOERSE MUENCHEN
Last update June 27, 2024 at 10:37 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | HSBC |
| WKN | TT1N6G |
| ISIN | DE000TT1N6G2 |
| Date issued | 25/03/2020 |
| Strike | 205.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.33 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.65 € |
|---|---|
| Lowest since issue | 0.84 € |
| Spread | 0.2 € |
| Spread % | 1.96% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
312.8
USD
Average target price
316.4
USD
Spread / Average Target
+1.16%
- Stock Market
- Certificates
- Certificat
